November 18, 2019 / 6:09 AM / a month ago

BRIEF-Roche To Present Data For 7 Approved And Investigational Medicines Across Multiple Types Of Breast Cancer

Nov 18 (Reuters) - Roche Holding AG:

* ROCHE TO PRESENT NEW AND UPDATED DATA FOR SEVEN APPROVED AND INVESTIGATIONAL MEDICINES ACROSS MULTIPLE TYPES OF BREAST CANCER AT THE 2019 SAN ANTONIO BREAST CANCER SYMPOSIUM

* STUDY RESULTS REFLECT ADVANCEMENTS IN HER2-POSITIVE, TRIPLE-NEGATIVE, AND HORMONE RECEPTOR-POSITIVE BREAST CANCER

* FOLLOW-UP DATA FROM PIVOTAL PHASE III APHINITY STUDY EVALUATING PERJETA PLUS HERCEPTIN AND CHEMOTHERAPY IN HER2-POSITIVE EARLY BREAST CANCER

* RESULTS FROM PHASE III FEDERICA STUDY CONFIRMING NON-INFERIORITY OF A FIXED-DOSE COMBINATION OF PERJETA AND HERCEPTIN ADMINISTERED UNDER SKIN Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below